ARWR

Arrowhead Pharmaceuticals, Inc.

September 15, 2026 · intraday

Rarity

2.80

Peak move

−12.41%

Float cap

$10.1B

Arrowhead Pharmaceuticals develops RNA interference (RNAi) therapeutics for diseases with a genetic basis. Its first approved product, REDEMPLO (plozasiran), treats familial chylomicronemia syndrome, and the company has a pipeline targeting severe hypertriglyceridemia and other conditions. It also licenses its technology to pharmaceutical partners.

• clinical_readoutSep 15

  Arrowhead Pharmaceuticals reported interim topline Phase 1/2a data for ARO-DIMER-PA, its dual-functional RNAi therapeutic targeting PCSK9 and APOC3 in mixed hyperlipidemia, showing mean maximal single-dose reductions in serum PCSK9 of 72% and APOC3 of 88%, with LDL-C down 54%, triglycerides down 73%, non-HDL cholesterol down 61% and ApoB down 50%, and dose escalation through 400 mg with no drug-related SAEs.

  Webbusinesswirenews.comWebinvestingnews.comWebbenzinga.comWebir.arrowheadpharma.comWebbusinesswire.com
• investor_daytime: see source

  At the Cantor Fitzgerald Global Healthcare Conference, Arrowhead CFO Daniel Apel and SVP Andy Davis said plozasiran (REDEMPLO) will not be out-licensed and will be fully commercialized in the US, that zodasiran is expected in 2028, that ARO-DIMER-PA targets a US market of about 20 million mixed hyperlipidemia patients, and that about 10% of prescriptions are switches from olezarsen.

  Webca.investing.comWebca.investing.comWebca.investing.com
• analyst_ratingSep 9

  Citi analysts led by Eric Joseph placed Arrowhead Pharmaceuticals under a 30-day catalyst watch ahead of anticipated Phase 1 trial results for the ARO-DIMER-PA mixed hyperlipidemia program, maintaining a Buy rating with a $108 price target.

  Webgurufocus.com